<DOC>
	<DOCNO>NCT02398669</DOCNO>
	<brief_summary>Study evaluate pharmacokinetics ( PK ) , safety tolerability single 10 mg dose lorcaserin hydrochloride obese pediatric subject 6 11 year age .</brief_summary>
	<brief_title>A Single Dose Pharmacokinetic Study Lorcaserin Hydrochloride Obese Pediatric Subjects 6 11 Years Age</brief_title>
	<detailed_description />
	<criteria>1 . Males female age 6 year 11 year ( 11 year 364 day ) , inclusive , Screening . 2 . BMI great equal 99th percentile age gender define : Age Boys Girls 6 21.6 23.0 7 23.6 24.6 8 25.6 26.4 9 27.6 28.2 10 29.3 29.9 11 30.7 31.5 less equal 44kg/m2 Screening . 3 . Provide write informed consent sign parent/legal guardian prior enter study undergo study procedure . A write verbal assent subject also obtain . 4 . Females age least 8 year negative serum Bhuman chorionic gonadotropin ( betahCG ) Visit 1 negative urine pregnancy test prior receive first dose study drug Visit 2 . 5 . Willing able comply aspect protocol . 6 . Able swallow single tablet . 1 . Clinically significant illness require medical treatment within 8 week clinically significant infection require medical attention within 4 week dose 2 . Evidence disease may influence outcome study within 4 week dose ( eg , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism ) 3 . Secondary ( chromosomal , endocrine , metabolic ) cause obesity ( eg , PraderWilli syndrome , Down 's Syndrome , untreated hypothyroidism , Cushing 's syndrome ) . 4 . Any history abdominal surgery may affect PK evaluation ( eg , hepatectomy , nephrotomy , digestive organ resection gastrointestinal procedure purpose weight loss , would slow gastric empty ) . 5 . Any clinically relevant symptom organ impairment find medical history , physical examination , vital sign , electrocardiogram ( ECG ) finding , laboratory test result require medical treatment Screening . 6 . Special needs subject unable comprehend trialrelated instruction ( eg , mild profound mental retardation , moderate severe cognitive developmental delay , pervasive developmental disorder , autism ) . 7 . Females sexually active . 8 . Ongoing epilepsy seizure disorder , use medication seizure disorder within 6 month Screening Screening Day 1 . 9 . History congestive heart failure , pulmonary arterial hypertension , congenital heart disease , organ transplantation . 10 . Resting heart rate le 50 great 120 beats/min Screening predose Day 1 . 11 . Systolic blood pressure ( BP ) great 140 mmHg less 90 mmHg diastolic blood pressure great 90 mmHg less 60 mmHg Screening predose Day 1 . 12 . Hypersensitivity study drug excipients . 13 . Significant change diet level physical activity within 1 month prior dose change weight great 5 kg within 3 month prior dose . 14 . Known human immunodeficiency virus ( HIV ) positive Screening . 15 . Active viral hepatitis ( B C ) demonstrate positive serology Screening . 16 . Unable attend schedule visit ( eg , lack transportation ) lack parent/guardian supervise study participation . 17 . Enrolled another clinical trial involve pharmacotherapy , medical device , within 30 day inform consent . 18 . Use drug serotonergic activity within 4 week dose , include limited selective serotoninnorepinephrine reuptake inhibitor ( SNRIs ) , selective serotonin reuptake inhibitor ( SSRIs ) , tricyclic antidepressant ( TCAs ) , bupropion , triptans , drug impair metabolism serotonin ( include monoamine oxidase inhibitor [ MAOIs ] , linezolid ) , dextromethorphan , lithium , tramadol , antipsychotic dopamine antagonist . 19 . Intake nutritional supplement , juice , herbal preparation food beverage may affect cytochrome P450 activity transporter ( eg , grapefruit , grapefruit juice , grapefruit containing beverage , apple orange juice , vegetables mustard green family [ eg , kale , broccoli , watercress , collard green , kohlrabi , brussels sprout , mustard ] charbroiled meat ) prohibit within 2 week dose . 20 . Intake herbal preparation contain St. John 's Wort prohibit within 4 week dose . 21 . Treatment within 4 week dose overthecounter weight loss product appetite suppressant ( include herbal weight loss agent ) , within 3 month dose prescription weight loss drug ( eg , phentermine , sibutramine , orlistat ) lipid dissolve injection ( eg , Lipodissolve ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Lorcaserin hydrochloride</keyword>
	<keyword>APD356</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>